Biovail Corporation
Pharmaceutical company amends 2004 stock option plan proposal
Published in Pharma Investments, Ventures and Law Weekly, July 11th, 2004
The amended plan will be subject to shareholder approval at Biovail's annual and special meeting on June 25, 2004.
Under the terms of the amended plan, the maximum number of common shares issuable pursuant to the exercise of options will be reduced from 10 million to 5 million. Further, the maximum number of common shares issuable pursuant to options to non-employee directors, together with the number of common shares issuable to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- Alliance Pharmaceutical Corp.
Pharmaceutical company receives commitments for $11M financing - Alnylam Pharmaceuticals, Inc.
Biopharmaceutical firm exercises underwriters' over-allotment option - BioNumerik Pharmaceuticals, Inc.
Pharmaceutical company files for initial public offering - CV Therapeutics, Inc.
Biopharmaceutical company sells $25M in convertible notes - Depomed, Inc.
Pharmaceutical company acquires remaining interest in subsidiary - Encysive Pharmaceuticals
Pharmaceutical company files $150M universal shelf registration statement - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
